Figure 4

Effects of the EGFR inhibitor erlotinib on ERK phosphorylation and cell proliferation. (A) Immunoblotting analysis of phosphorylated ERK (p-ERK), ERK , and ACTB levels in Hep3B and LR7.5-3B cells that had been treated with 3 μM lenvatinib or the indicated concentrations of erlotinib for 4 h. (B, C) Cell proliferation was analyzed by Cell Counting Kit 8 (CCK-8) assays in Hep3B (3B) (B) and LR7.5-3B (LR) (C) cells that had been treated with or without 0.5 μM erlotinib at the indicated times (n = 4 per treatment). Representative results are shown. (D) Immunoblotting analysis of phosphorylated ERK (p-ERK), ERK and ACTB levels in Hep3B and LR7.5- 3B cells that had been treated with or without 3 μM lenvatinib, alone or combined with 0.5 or 5 μM erlotinib for 4 h. (E,F) Cell proliferation was analyzed by Cell Counting Kit 8 (CCK-8) assays in Hep3B (3B) (E) and LR7.5-3B (LR) (F) cells that had been treated with or without 3 μM lenvatinib, alone or combined with 0.5 μM erlotinib, at the indicated times (n = 4 per treatment). The intensity with the internal control were indicated. Two independent experiments of were performed, and representative results are shown. *p < 0.05.